



Novel Synthesis and Anti-microbial Activity Study of Innovative Mannich Bases Containing 2-Phenoxy-1,3,2-dioxaphospholanes and Indole Systems

SUBBA NARAYANA KANCHANA*, VENKATARAMUDU BURRA and L. K. RAVINDRA NATH

Department in Chemistry, S.K. University, Anantapur, Andhra Pradesh, India.

*Corresponding author E-mail: drsubbukanchana@gmail.com

<http://dx.doi.org/10.13005/ojc/300354>

(Received: May 28, 2014; Accepted: July 01, 2014)

ABSTRACT

In the present study, synthesis, characterization, antimicrobial activity on some novel pyrazolone derivatives has been taken up. The primary amines were diazotized with sodium nitrite and HCl mixture at 0-5 °C which were further coupled with ethyl acetoacetic ester to afford phenyl diazonium acetoacetic esters (II). Condensation of 4-substituted aryl hydrazono acetoacetic ester, 4-hydrazinylbenzenamine in the presence of catalytic amount of DMF under microwave irradiation afforded (4Z)-4-(2-substituted aryl hydrazono)-1-(4-aminophenyl)-3-methyl-1H-pyrazol-5(4H)-one (III). Subjecting (III) to anhydrous K₂CO₃ in DMF for 8 hours afforded 2-{4-[(4Z)-4-(2-substituted aryl hydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino} acetate (IV) which was further reacted with hydrazine hydrate to afford 2-{4-[(4Z)-4-(2-substituted aryl hydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenylamino} acetohydrazide (V). Reaction of (V) and Isatin (VI b) in DMF afforded (4Z)-2-(4-[(15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide (VII). Compound (VII) was subsequently subjected to Mannich reaction with cyclic secondary amines (piperidine/morpholine/N-methyl piperidine) in the presence of formaldehyde in DMF to afford (4Z)-2-(4-[(15Z)-4-(2-substituted aryl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl]phenylamino)-N'-(2-oxo-1-[(piperidin-1-yl)methyl]indolin-3-ylidene)acetohydrazide (VIII) which was characterized by I.R, ¹H NMR and Mass data. The anti-bacterial activity of synthesized compounds was studied by the disc diffusion method against pathogenic bacteria and fungi.

Key words: Mannich reaction, Mannich base, Anti-microbial activity.

INTRODUCTION

Mannich bases and their derivatives have many attractive therapeutic use and applications, in paint and polymer chemistry as hardeners, cross linkers, reaction accelerations¹⁻² etc. However, the most important applications are in the field of

pharmaceutical products³⁻⁴. Studies on antineoplastic drugs, analgesic drug, antibiotic drugs etc⁵⁻⁹, including labeled molecules¹⁰⁻¹² have received particular attention in the recent past. Mannich bases can either directly be employed or used as intermediates in chemicals synthesis.

Literature review

All previous reported synthetic routes were reviewed and synthesis and biological activity of various Mannich bases are reported. Other similar synthetic routes also reported with different derivatives and all were reviewed completely⁽¹³⁻²²⁾. Pandeya S.N and Usha L⁽²³⁾ *et.al.*, Mannich condensation on 3-sulfadiazinylsarin in the presence of formaldehyde and secondary furnished 3-aminomethyl analogs which were evaluated as antimicrobial agents.

Pandeya S.N and Sriram D²⁴ *et. al.*, have reported the synthesis and anti-HIV activity of Mannich bases of isatin.

Lingaiah N²⁵ *et. al.*, have reported the synthesis and anti-inflammatory activity of some 1-aminomethyl-3-benzoylhydrazono-2-indolinones. Renukadevi P⁽²⁶⁾ *et.al.*, have reported the synthesis and antimicrobial activity of 1-substitutedaminomethyl-3-(5-substituted-3-phenylindol-2-yl-carbohydrazide)-2-indolinones. Pandeya *et al*⁽²⁷⁾ Bhat AR Shenoy G.G and have reported the synthesis, antibacterial and antiviral activities of isatin derivatives.

Sridhar S.K²⁸ *et.al.*, Isatins have been reacted with 3-(4-pyridyl)-4-amino-5-mercapto-4H-1,2,4-triazole to form Schiff bases and the N-Mannich bases of these compounds were synthesized by reacting them with formaldehyde and several secondary amines. The compounds have been evaluated for their antimicrobial activity. Figure-1 represents the all published methods as discussed above.

Objective

Pyrazolones, pyrazoles and related heterocycles possess various types of biological activities. A good deal of importance is given to pyrazoline derivatives. It is due to their wide use in medical chemistry and some of them possess antituberculosis antineoplastic anti fertility and anti thyroid activity. The antibacterial activity of Mannich bases has been well established. In view of these observations, it appeared of interest to synthesize some novel Mannich bases bearing azomethine pyrazoline-5-one and indole moieties.

EXPERIMENTAL

Synthesis of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene) acetohydrazide

Final product (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene) acetohydrazide involves eight steps. Each synthetic step reaction process and products information as discussed below.

Step-I: Synthesis of substituted diazonium chloride and Step-II: Synthesis of phenyl diazonium acetoacetic ester



The required substituted anilines were diazotized with sodium nitrite and HCl mixture at 0-5°C and it is coupled with ethyl acetoacetic ester Step-I product to afford phenyl diazonium acetoacetic ester Step-II product.

Reaction process for step-I

The required primary amine is dissolved in a suitable volume of water containing 2.5-3.0 equivalents of hydrochloric acid (or sulfuric acid) by the application of heat of necessary. The solution thus obtained is cooled to 0°C when the amine hydrochloride (or sulphate) usually crystallizes. The temperature is maintained at 0-5°C, and the aqueous solution of sodium nitrite is added portion wise till there is free nitrous acid. The solution is tested for the later with an external indicator (moist potassium iodide starch paper). An excess of acid is always maintained to stabilize the diazonium, acid is harmful; the concentration of the acid is reduced to optimum value. The similar procedure is adopted for the preparation of other substituted phenyl diazonium chlorides.

Reaction process for step-II

A solution of sodium acetate (1.0g) in 100ml of aqueous alcohol (50%) is added to a solution of ethyl acetoacetate (0.1 mol) in 50 ml of ethanol and the mixture is added to 0°C. to this cold mixture, the corresponding diazonium chloride is added gradually till turbidity is observed. The addition is continued till yellow crystals separated out. These crystals are filtered, washed with water and dried.



Step-III: Synthesis of (4Z)-4-(2-substituted aryl hydrazono)-1-(4-aminophenyl)-3-methyl-1H-pyrazol-5(4H)-one

Condensation of 4-substituted aryl hydrazono acetoacetic ester, 4-hydrazinylbenzenamine in the presence of catalytic amount of dimethyl formamide under microwave irradiation afford (4Z)-4-(2-substituted aryl hydrazono)-1-(4-aminophenyl)-3-methyl-1H-pyrazol-5(4H)-one. In a typical experimental procedure, a mixture of aryl hydrazono acetoacetic ester, 4-hydrazinylbenzenamine and dimethyl formamide (10 drops) was subjected to microwave irradiation at 150W intermittently at 30sec intervals for 2 minutes. After complete conversion as indicated by TLC, the reaction mixture was cooled and treated with cold water. The precipitate (4Z)-4-(2-substituted aryl hydrazono)-1-(4-aminophenyl)-3-methyl-1H-pyrazol-5(4H)-one was filtered recrystallized from ethanol. The yield is 88%

Reaction process

Condensation of 4-substituted aryl hydrazono acetoacetic ester step-II product and 4-hydrazinylbenzenamine in the presence of catalytic amount of dimethyl formamide under microwave irradiation afforded (4Z)-4-(2-substituted aryl hydrazono)-1-(4-aminophenyl)-3-methyl-1H-pyrazol-5(4H)-one. In typical experimental procedure, a mixture of arylhydrazono acetic ester step-II product, 4-hydrazinylbenzenamine and dimethyl formamide (10 drops) was subjected to microwave irradiation at 150W intermittently at 30 sec intervals for 2 minutes. After complete conversion as indicated by TLC, the reaction mixture was cooled and heated with cold water. The precipitate Step-III product was filtered recrystallized from ethanol M.P.182°C, yield 88%.
Step-IV: Synthesis of ethyl 2-[4-[(4Z)-4-(2-substituted aryl hydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino] acetate

A mixture of, anhydrous K_2CO_3 and DMF was stirred at room temperature for 8 hours. The reaction mixture was diluted with ice cold water. The separated solid was identified as ethyl 2-[4-[(4Z)-4-(2-substituted aryl hydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino] acetate.

Reaction process

A mixture of Step-III product, anhydrous

K_2CO_3 and DMF was stirred at room temperature for 8 hours. The reaction mixture was diluted with ice cold water. The separated solid was identified as Step-IV product. This was collected by filtration, and recrystallized from ethanol. M.P. 204°C, yield 78%. Elemental analysis found C: 58.22%, H: 5.62%, N: 19.55%, O: 16.75%. Calcd: C: 58.32%, H: 5.59%, N: 19.43%, O: 16.65%.

Step-V: Synthesis (4Z)-2 -(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl) phenylamino)-N'-(2-oxoindolin-3-ylidene) acetohydrazide

A solution of step-IV product and hydrazine hydrate in ethanol was refluxed for 5 hours. The reaction mixture was cooled and poured on to ice cold water with stirring. The separated solid was filtered, washed with water and recrystallized from ethanol to afford 2-[4-[(4Z)-4-(2-substituted aryl hydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino] acetohydrazide.

Reaction process

A solution of step-IV product and hydrazine hydrate in ethanol was refluxed for five hours. The reaction mixture was cooled and poured into ice cold water with stirring. The separated solid was filtered washed with water and recrystallized from ethanol to afford step-V product.

Step-VI: Synthesis of Isatin

The synthon, isatin was prepared by the procedure described by Marvel and Heins⁴¹.

Reaction process for step-VI (a)

In a one litre R.B flask 22g of chloral hydrate and 300ml of water placed. To this 325g of crystallized sodium sulphate, 12g of aniline (in 75ml of water), 12ml of conc.HCl and 27g of hydroxyl amine hydrochloride (in 25ml of water) were added. The flask was heated over a wire gauge for about 40-45 min. after one or two minutes of vigorous boiling, the reaction mixture was cooled and the separated solid was filtered and air-dried, yield 16gm, M.P. 175°C. (lit³⁵. M.P.175°C).

Reaction process for step-VI (b)

In a one litre R.B. flask 8ml of conc. H_2SO_4 was placed and warmed at 50°C, to this 18g of dry iso-nitroso acetanilide was added. The temperature

was kept between 60-70°C using external cooling. After the addition of the iso-nitroso compound, the reaction mixture was heated to 80°C and kept at this temperature for about 10 minutes. Then the reaction mixture was cooled to room temperature and poured on to crushed ice. The precipitated isatin was filtered with suction, washed several times with cold water to remove the H₂SO₄ and then dried in the air, yield 12g M.P.190°C (lit³⁵.M.P.189-192°C).

Step-VII: Synthesis of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide

Condensation of 2-{4-[(4Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino} acetohydrazide step-V product with Isatin step-VI product in DMF furnished the corresponding (4Z)-2-(4-((15Z)-4-(2-substituted aryl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide step-VII product in excellent yields.

In a typical example, a mixture of step-V product (R=H) and step-VI product in 1:1 molar preparation when heated in DMF and water bath for 45 minutes yielded a compound M.P. 192°C. Based on spectral data, the compound was assigned structure as (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide Step-VII product (R=H).

Reaction process

A mixture of step-V product (R=H) and step-VI (b) product in 1:1 proportion heated in DMF (10 ml) on water bath for 45 minutes yielded a compound was filtered, washed with water and recrystallized from methanol to afford step-VII product yield M.P. 192°C.

Step-VIII: Synthesis of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene)acetohydrazide

Compounds step-VII product was subjected to Mannich reaction with cyclic secondary amines(piperidine/morpholine/N-methyl piperidine)

in the presence of formaldehyde in DMF to give (4Z)-2-(4-((15Z)-4-(2-substituted aryl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene)acetohydrazide Step-VIII product (R = H (a)) in excellent yields.

In a typical example, a mixture of hydrazone step-VII product (R = H), with aqueous formaldehyde and piperidine in DMF for six hours at room temperature yielded a single product which was identified as (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene)acetohydrazide step-VIII product (R = H), on the basis of its spectroscopic data.

Reaction process

A mixture of hydrazone step-VII product (R=H) is stirred with aqueous formaldehyde and piperidine in DMF for 6 hours at room temperature and diluted with water. The solid thus separated was filtered, washed with water and recrystallized from methanol to give step-VIII product yield: M.P.:158°C.

Similar synthesis

Similar synthesis has applied to other functional group derivatives and synthesized the other members of the series step-V to step-VIII products and their characterization also completed and characterization results are discussed in the results and discussion part. (R = CH₃; OC₂H₅; Cl; H (b-f)).

RESULTS AND DISCUSSION

Step-V Synthesis (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide

The compounds synthesized Step-V Product have been characterized by means of their elemental analysis, I.R, ¹NMR and Mass data.

IR Spectra

The IR (KBr) spectra of 2-{4-[(4Z)-4-(2-substituted aryl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino} acetohydrazide Step-V Product (a) absorptions around 3445, 3425, (2 bands) 3305,1620,1665,1460 and 1455 cm⁻¹ due

to $-\text{NH}_2$, $>\text{NH}$ exo $>\text{C}=\text{N}$, cyclic carbonyl and five membered hetero cyclic ring respectively.

^1H NMR Spectrum

The ^1H NMR (200MHz) spectra of 2-[4-[(4Z)-4-(2-phenylhydrazono)-4, 5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino} acetohydrazide

Table 1: IR spectral data for Step-V Product

Step-V Product	R	ν_{max}				Mass (M)
		NH_2	NH	C = N	C = O	
a	H	3445				365.39
		3425	3305	1620	1665	
b	CH_3	3420				379.42
		3400	3285	1610	1650	
c	OCH_3	3425				395.42
		3405	3200	1615	1555	
d	OC_2H_5	3435				409.44
		3415	3300	1615	1660	
e	Cl	3420				399.83
		3400	3275	1610	1645	
f	Br	3444				444.29
		3424	3290	1606	1650	

Step-V Product a-f were recorded in DMSO-d_6 for three protons. The N- CH_2 -CO proton ^1H NMR spectrum of Step-V Product a is shown figure-2. The signal due to the methyl group appeared as a singlet at δ 1.0, integrating

into resonance at 3.85 as a singlet. The NH-N=C appeared as singlet at 7.0

Table 2: ^1H NMR spectral data for Step-V Product

Step-V Product	R	^1H NMR (200MHz) (DMSO-d_6) (δ ppm)
a	H	1.2(s, 3H, CH_3), 2.1(s, 2H, NH_2), 3.8 (s, 2H, N- CH_2 -CO), 4.1 (s, 1H, Ar-NH), 6.8 (s, 1H, Ar-NH), 7.1- 7.3(m, 5H, C_6H_5) 7.4 (d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 8.35 (s, 1H, CONH).
b	CH_3	0.9(s, 3H, CH_3), 1.16 (s, 3H, CH_3) 2.0 (s, 2H, NH_2), 3.9(d, 2H, N- CH_2 -CO).4.0 (s,1H, Ar-NH), 6.9 (s, 1H, Ar-NH), 7.1- 7.3(m, 4H, C_6H_4) 7.4 (d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 8.35(s, 1H, CONH)
c	OCH_3	1.1(s, 3H, CH_3), 2.02 (s, 2H, NH_2), 3.7 (s, 3H, OCH_3), 3.95(d, 2H, N- CH_2 -CO),4.1(s,1H, Ar-NH), 6.9 (s, 1H, Ar-NH), 7.1- 7.3(m, 4H, C_6H_4), 7.4 (d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 8.35 (s,1H, CONH)
d	OC_2H_5	1.0(s, 3H, CH_3), 1.1(t, 3H, CH_3), 2.02 (s, 2H, NH_2), 3.2 (q, 2H, O- CH_2), 3.95(d, 2H, N- CH_2 -CO), 4.1 (s, 1H, Ar-NH), 6.9 (s, 1H, Ar-NH), 7.1-7.3(m,4H, C_6H_4),7.4 (d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 8.35 (s,1H, CONH)
e	Cl	1.1(s, 3H, CH_3), 2.1 (s, 2H, NH_2), 3.95(d, 2H, N- CH_2 -CO), 4.1 (s, 1H, Ar-NH), 6.8 (s, 1H, Ar-NH), 7.1-7.3 (m, 4H, C_6H_4), 7.4 (d, 2H, C_6H_4), 7.7(d, 2H, C_6H_4), 8.35 (s, 1H, CONH)
f	Br	1.04(s, 3H, CH_3), 2.0 (s, 2H, NH_2), 3.9 (d, 2H, N- CH_2 -CO), 4.05 (s, 1H, Ar-NH), 6.8 (s, 1H, Ar-NH), 7.1-7.3 (m, 4H, C_6H_4), 7.4 (d, 2H, C_6H_4), 7.7(2H, C_6H_4), 8.35 (s, 1H, CONH)

The NMR signal for CO-NH is noticed at δ 8.4 as a broad singlet. The NH₂ signal is observed at δ 2.1 as a broad singlet.

Step-VII: Synthesis of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide

The structural assignments to these compounds Step-VII Product were based on the analytical and spectral data.

IR Spectra

The IR (KBr) spectra of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide Step-VII Product(a) showed characteristic strong absorption bands around 3205 (NH), 3170 (Indole NH), 1602 (C = N), 1656 (pyrazoline C = O), 1700 (C = O) and 1618 (CONH). The spectral data are recorded in Table – 3

Table 3: IR data for Step-VII Product

Step-VII Product	R	ν_{\max} in cm^{-1}					
		NH	Indole NH	C = N	Pyrazoloine C = O	Indole C = O	CO-NH
a	H	3205	3170	1602	1656	1700	1618
b	CH ₃	3180	3140	1600	1654	1700	1622
c	OCH ₃	3100	3150	1505	1654	1701	1625
d	OC ₂ H ₅	3195	3155	1604	1654	1701	1624
e	Cl	3175	3140	1605	1654	1701	1624
f	Br	3190	3150	1604	1654	1701	1624

¹HNMR Spectra

The ¹HNMR (200 MHz) spectrum of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-

oxoindolin-3-ylidene)acetohydrazide Step-VII Product (a) in DMSO – d₆ showed the following signals δ 1.1 (s, 3H, CH₃), δ 10.93 (s, 1H, Ar-NH), δ 5.78 (s, 2H, N-CH₂-CO), δ 12.75 (s, 1H, Indole NH),

Table 4: ¹HNMR spectral data for Step-VII Product

Step-VII Product	R	¹ HNMR (200MHz) (DMSO-d ₆) (δ ppm)
a	H	1.1 (s, 3H, CH ₃), 4.1 (s, 1H, Ar-NH), 5.8 (s, 2H, N-CH ₂ -CO), 6.8 (s, 1H, Ar-NH), 7.0-7.1 (m, 9H, C ₆ H ₄), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 10.9 (s, 1H, CO-NH), 12.75 (s, 1H, Indole-NH)
b	CH ₃	1.0 (s, 3H, CH ₃), 1.15 (s, 3H, CH ₃), 4.15 (s, 1H, Ar-NH), 5.8 (N-CH ₂ -CO), 6.8 (s, 1H, Ar-NH), 7.0-7.1(m, 8H, C ₆ H ₄), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 11.0 (s, 1H, CONH), 12.75 (s, 1H, Indole-NH).
c	OCH ₃	1.1 (s, 3H, CH ₃), 3.25 (s, 3H, OCH ₃), 4.1 (s, 1H, Ar-NH), 5.8 (N-CH ₂ -CO), 6.8 (s, 1H, Ar-NH), 7.0-7.1(m, 8H, C ₆ H ₄), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 10.95 (s, 1H, CONH), 12.75 (s, 1H, Indole-NH).
d	OC ₂ H ₅	1.0 (s, 3H, CH ₃), 1.2 (t, 3H, CH ₃), 3.2 (q, 2H, O-CH ₂), 4.15 (s, 1H, Ar-NH), 5.8 (N-CH ₂ -CO), 6.8 (s, 1H, Ar-NH), 7.0-7.1(m, 8H, Ar-H), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 10.9 (s, 1H, CONH), 12.75 (s, 1H, Indole-NH).
e	Cl	1.05 (s, 3H, CH ₃), 4.1 (s, 1H, Ar-NH), 5.8 (s, 2H, N-CH ₂ -CO), 6.8 (s, 1H, Ar-NH), 7.0-7.1 (m, 8H, C ₆ H ₄), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 10.9 (s, 1H, CONH), 12.75 (s, 1H, Indole-NH).
f	Br	1.0 (s, 3H, CH ₃), 4.0(s, 1H, Ar-NH), 5.8 (s, 2H,N-CH ₂ -CO),6.8 (s, 1H, Ar-NH), 7.0-7.1 (m, 8H, C ₆ H ₄), 7.4 (d, 2H, C ₆ H ₄), 7.7 (d, 2H, C ₆ H ₄), 10.9 (s, 1H, CO-NH), 12.75 (s, 1H, Indole-NH).

δ 6.9-7.7 (m, 13H, Ar-H). The spectral data recorded in Table 4.

Mass spectra

The mass spectra of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide Step-VII Product (a) (R=H) showed molecular ion (M^+) peaks at m/z 494.

The mass spectral fragmentation patterns of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene)acetohydrazide Step-VII Product (a) (R=H) are analyzed. The molecular ion observed at m/z 494 (15.5%), other important

peaks appeared at m/z 477 (31.2%), 417 (16.5%), 389 (23.1%), 334 (100%) 323 (24.1%), 293 (12.1%), 277(21.9%), 202 (20.1%).

Step-VIII: Synthesis of (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene)acetohydrazide

The structure of this newly synthesized compounds VIII (a-f) where established on the basis of an elemental analysis and spectra data (IR and ^1H NMR).

IR spectra

The IR (KBr) spectra of (4Z)-2-(4-((15Z)-

Table 5: IR Spectral data for Step-VIII Product

Step-VIII Product	R	X	ν_{max} in cm^{-1}					
			NH	C=N	Pyrazole C=O	Indole C=O	=O	NH
a	H	CH_2	3195	1610	1676	1720	1654	2933
e	H	O	3193	1620	1681	1710	1660	2920
f	H	N	CH_3	3180	1617	1666	1710	1657

4-(2-phenylhydrazono)-4,5-dihydro -3-methyl -5 -oxopyrazol -1-yl) phenylamino)-N'-(2-oxo-1-((piperidin-1-yl) methyl) indolin-3-ylidene) acetohydrazide Step-VIII Product (a) (Mannich

base) exhibited characterize bands around 3195 (NH), 1610 (C =N), 1676 (pyrazole C=O), 1654 (C – NH) and 2933cm^{-1} (CH_2). The spectral data furnished in Table 5.

Table 6: ^1H NMR Spectral data for Step-VIII Product

Step-VIII Product	R	X	^1H NMR (200MHz) (DMSO-d_6) (δ ppm)
a	H	CH_2	1.1 (s, 3H, CH_3), 1.45 [(s, 6H, (CH_2) $_2$], 2.56 (t, 4H, - CH_2 -N- CH_2), 4.1 (s, 1H, Ar-NH), 4.5 (s, 2H, -N- CH_2 -N), 5.9 (s, 2H, N- CH_2 -CO), 6.8 (s, 1H, Ar-NH), 7.1-7.2 (m, 5H, C_6H_4), 7.4(d, 2H, C_6H_4), 7.7(d, 2H, C_6H_4), 9.0 (s, 1H, CONH).
e	H	O	1.1 (s, 3H, CH_3), 2.6 (t, 4H, CH_2 -N- CH_2), 3.7 (t, 4H, CH_2 -O- CH_2), 4.15(s, 1H, Ar-NH), 4.5 (s, 2H, N- CH_2 -N), 6.0 (s, 2H, N- CH_2 -CO), 6.8 (s, 1H, Ar-NH), 7.1-7.2 (m, 5H, C_6H_4), 7.4(d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 9.0 (s, 1H, CONH).
f	H	N- CH_3	1.1 (s, 3H, CH_3), 2.4 (t, 4H, CH_2 -N- CH_2), 2.7 (t, 4H, CH_2 -N- CH_2), 4.0 (s, 1H, Ar-NH), 4.2(s, 3H, N- CH_3), 4.5 (s, 2H, N- CH_2 -N), 6.0 (s, 2H, N- CH_2 -CO), 6.8 (s, 1H, Ar-NH), 7.1-7.2 (m, 5H, C_6H_4), 7.4(d, 2H, C_6H_4), 7.7 (d, 2H, C_6H_4), 9.0 (s, 1H, CONH).

¹HNMR Spectra

The ¹HNMR (200 MHz) spectra of (4Z)-2-(4-((15Z)-4-(2-phenyl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl) methyl)indolin-3-ylidene) acetohydrazide Step-VIII Product (a) (R = H, X = CH₂), 2-{4-[(4Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenylamino}(2-oxo-1-morpholino-1-ylmethyl,2-dihydro-indol-3-ylidene) acetohydrazide Step-VIII Product (g) (R = H, X = C) and (4E)-2-(4-((32Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-

N'-(1-((4-methylpiperazin-1-yl) methyl)-2-oxoindolin-3-ylidene)acetohydrazide Step-VIII Product (h) (R = H, X = N-CH₃) were recorded in DMSO-d₆, the data are recorded in Table 6. The appearance of signal at δ4.5 due to N-CH₂-N, confirmed the formation of Mannich bases.

Mass spectra

The mass spectra of (4Z)-2-(4-((15Z)-4-(2-phenyl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)indolin-3-ylidene)

Table 7: Characterization data for Step-V Product

Step-V Product	R	m.p. (°C)	Yield (%)	Mol. Formula	Found (%) – Calcd (%)					
					C	H	N	O	Cl	Br
a	H	152	65	C ₁₈ H ₁₉ N ₇ O ₂	59.25 (59.17)	5.32 (5.24)	26.90 (26.83)	8.83 (8.76)		
b	CH ₃	153	60	C ₁₉ H ₂₁ N ₇ O ₂	60.24 (60.15)	5.65 (5.58)	25.92 (25.84)	8.55 (8.43)		
c	OCH ₃	156	75	C ₁₉ H ₂₁ N ₇ O ₃	57.80 (57.71)	5.43 (5.35)	24.84 (24.80)	12.29 (12.14)		
d	OC ₂ H ₅	168	80	C ₂₀ H ₂₃ N ₇ O ₃	58.79 (58.67)	5.78 (5.66)	24.09 (23.95)	11.84 (11.72)		
e	Cl	174	75	C ₁₈ H ₁₈ ClN ₇ O ₂	54.22 (54.07)	4.70 (4.54)	24.67 (24.52)	8.24 (8.00)	9.01 (8.87)	
f	Br	169	65	C ₁₈ H ₁₈ BrN ₇ O ₂	48.78 (48.66)	4.26 (4.08)	22.17 (22.07)	7.26 (7.20)		18.07 (17.98)

Table 8: Characterization data for Step-VII Product

Step-V Product	R	m.p. (°C)	Yield (%)	Mol. Formula	Found (%) – Calcd (%)					
					C	H	N	O	Cl	Br
a	H	214	70	C ₂₆ H ₂₂ N ₈ O ₃	63.34 (63.15)	4.66 (4.48)	22.71 (22.66)	9.86 (9.71)		
b	CH ₃	241	70	C ₂₇ H ₂₄ N ₈ O ₃	63.95 (63.77)	4.94 (4.76)	22.17 (22.03)	9.61 (9.44)		
c	OCH ₃	234	70	C ₂₇ H ₂₄ N ₈ O ₄	62.00 (61.82)	4.81 (4.61)	21.51 (21.36)	12.34 (12.20)		
d	OC ₂ H ₅	224	75	C ₂₈ H ₂₆ N ₈ O ₄	62.62 (62.44)	5.07 (4.87)	20.95 (20.81)	12.07 (11.88)		
e	Cl	225	75	C ₂₆ H ₂₁ ClN ₈ O ₃	59.19 (59.04)	4.16 (4.00)	21.32 (21.18)	9.19 (9.07)	6.88 (6.70)	
f	Br	243	80	C ₂₆ H ₂₁ BrN ₈ O ₃	54.64 (54.46)	3.83 (3.69)	19.70 (19.54)	8.49 (8.37)		8.55 (13.94)

acetohydrazide Step-VIII Product (a) (R= H, X = CH₂) exhibited the molecular (M⁺) ion peak at m/z 591.

The fragmentation pattern analyzed with mass spectrum for (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl)methyl)

indolin-3-ylidene). The molecular ion (M⁺) "A" was observed at m/z 591 (12.5%), other important peaks appeared at m/z 562 (21.4%), 548 (25.8%), 472 (20.1%), 452 (17.2%), 420 (31.4%), 390 (14.5%), 334 (100%), 277 (28%).

Microbial activity

Mannich bases *step-VIII product (a,e,f)*

Table 9: Characterization data for Step-VIII Product

Step-VIII Product	X	R	m.p. °C	Yield (%)	Mol. Formula	Found (%) – Calcd (%)					
						C	H	N	O	Cl	Br
a	H	CH ₂	158	70	C ₃₂ H ₃₃ N ₉ O ₃	65.13 (64.96) (64.24)	5.76 (5.62) (5.87)	21.50 (21.31) (19.83)	8.29 (8.11) (10.07)		
e	Cl	CH ₂	161	75	C ₃₂ H ₃₂ ClN ₉ O ₃	61.54 (61.39)	5.30 (5.15)	20.22 (20.13)	7.78 (7.67)	5.82 (5.66)	
f	Br	CH ₂	160	80	C ₃₂ H ₃₂ BrN ₉ O ₃	57.45 (57.32) (62.72)	4.95 (4.81) (5.26)	18.93 (18.80) (21.24)	7.28 (7.16) (10.78)		12.03 (11.92)

have good antifungal activity against *Aspergillus Niger* NCCS 1196 and *Candida albicans* NCCS 2106. In this series chloro, bromo and nitro, p-phenyl syndronyl, p-tolyl syndronyl and N-phenyl syndronyl showed good antifungal activity against *Aspergillus Niger* and *Candida albicans* at the concentration of 250 µg/ml.

ACKNOWLEDGEMENTS

The authors express their grateful thanks to Sri Krishnadevaraya University- Anantapur, for providing support for this research.

CONCNLUSION

Synthesis and biological activity of Mannich bases has developed and characterized. In this research, authors have developed mannich bases with new synthetic process.

Product-I

(4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene) acetohydrazide.

Product-II

(4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene) acetohydrazide.

Product-III

(4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxo-1-((piperidin-1-yl) methyl)indolin-3-ylidene) acetohydrazide.

A solution of ethyl 2-{4-[(4Z)-4-(2-substituted aryl hydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl] phenyl amino} acetate Step-IV product and hydrazine hydrate in ethanol was refluxed for five hours afforded (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene) acetohydrazide Step-V product Condensation of 4 with isatins Step-VI product afforded (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl)phenylamino)-N'-(2-oxoindolin-3-ylidene) acetohydrazide Step-VII product. Amino methylation of Step-VII product

with formaldehyde and cyclic secondary amines (piperidine/morpholine/N-methyl piperazine) in DMF furnished (4Z)-2-(4-((15Z)-4-(2-phenylhydrazono)-4,5-dihydro-3-methyl-5-oxopyrazol-1-yl) phenylamino)-N'-(2-oxo-1-((piperidin-1-yl) methyl) indolin-3-ylidene) acetohydrazide Step-VIII product (Mannich bases).

The structures of these newly synthesized compounds Step-V product, Step-VII product and Step-VIII product were established on the basis of their elemental analysis and spectral (IR, ¹HNMR and MS) data.

REFERENCES

- Tramontini, M.; Angioloni, L. *Mannich-Bases, Chemistry and Uses*, CRC, Boca Raton, F.L. (1994).
- Ared, M.; Westermann, B.; Risch, N. *Angew. Chem Int Ed.* **1998**, *37*, 1044.
- Sridhar, S. K.; Pandya, S. N.; Stables, J. P.; Ramesh, A. *Eur. J. Pharm. Scien.*, **2002**, *16*(3), 129.
- Dimmock, J. R.; Kumar, P.; *Curr. Med. Chem.* **1977**, *4*(1), 1-22.
- Poplevskaya, I. A.; Kondauoru, G. N.; Abdullin, K. A.; Shipunova, L. K.; Chermanova G. B.; Kabiev, O. K. *Tr. Inst. Khim. Nauk. Kaz, SSR.* 1980, *52*, 52; *Chem. Abstr.*, **1981**, *94*, 120781.
- Against, P. C.; Krisch, G.; Wierzbicki, M.; Lepage, F.; Cagniant, D.; Loebenber, D.; Parmergianin and Scherlock, R. *Eur. J. Med. Chem.* **1980**, *15*, 439.
- Korea Inst. Of Science and Technology. *Jpn. Kokai Tokkyo Koho, JP.* **1983**, *5*, 867, 693. *Chem. Abstr.* **1983**, *99*, 7047A.
- Dimmock, J. R.; Raghavan, S. K.; Logan, B. M.; Bigam, G. E. *Eur. J. Med. Chem.* **1983**, *18*, 249.
- Bundgard, H.; *Methods in Enzymology.* **1985**, *112*, 347.
- Masuda, K.; Toga, T.; Hayashi, N. *J. Labelled Compd.* **1975**, *11*, 301; *Chem. Abstr.* **1976**, *84*, 121730f.
- Fowler, J. S. *J. Org. Chem.* **1977**, *42*, 2637.
- Schreier, E. *Helv. Chim. Acta.* **1977**, *59*, 585.
- Gadre, J. N.; Dubhashi, V. B. *Indian J. Heterocycl. Chem.* **1994**, *3*, 181.
- Gahane, D. R.; Khapekan, K. D, Sharma, V. C.; Gaikwad, N. J. *Indian J. Pharm. Sci.*, **1998**, *60*, 275.
- Rajasekaran, A.; Mahesh, R.; Parimoo P. *Indian J. Heterocycl. Chem.* **1998**, *8*, 151.
- Balakrishna, K.; Prashantha, G.; Ananda, K. *Indian J. Chem.* **1999**, *38B*, 1295.
- Pandeya, S. N.; Shiram, D.; Nath, G.; Declercq, E.; *Indian J. Pharm. Sci.* **1999**, *9*, 358.
- Sridhar, S. K.; Pandeya, S. N.; Bajpai, S. K.; Manjula, H. *Indian Drugs.* **1999**, *36*, 412.
- Mojtahedi, M. M.; Sharifi, A.; Mohsenzadeh, F.; Saidi, M. R. *Synth Commun.* **2000**, *30*, 69.
- Baruah, S. G.; Prajapati, D.; Sandhu, J. S. *Synlett.*, **2000**, *15*, 341.
- Pandeya, S. N.; Sriram, D.; Nath, G.; Declercq, E. *Arznein-Forsch/Drug Res.* **2000**, *50*, 55.
- Pandeya, S. N.; Sriram, D.; Nath, G.; Declercq, E. *Eur. J. Med. Chem.* **2000**, *35*, 249.
- Pandeya, S. N.; Usha, L. A.; Bajpal, S. K. *Indian J. Heterocycl. Chem.* **1977**, *6*, 313.
- Pandeya, S. N.; Sriram, D.; Declercq, E.; Pannecouque, C.; Witvrouw, M. *Indian J. Pharm. Sci.* **1998**, *60*, 207.
- Lingaiah, N.; Narender. R.; Dattatreya, M. A. *Indian J. Chem.* **1998**, *378*, 1254.
- Renukadevi, P.; Biradan, J. S. *Indian J. Heterocycl. Chem.* **1999**, *9*, 113.
- Bhat, A. R.; Shenoy, G. G.; Mohan, K. *Indian J. Heterocycl. Chem.* **2000**, *9*, 319.
- Sridhar, S. K.; Ramesh. *Aj. Biol. Pharm. Bull.* **2001**, *24*, 1149.
- Varma, R. S.; Rastogi, N. *Indian J. Heterocycl. Chem.* **2001**, *11*, 123.
- Varma, R. S.; Pachauri, G. *Indian J. Heterocycl. Chem.* **2002**, *12*, 49.
- Varma, R. S.; Rastogi, N.; Singh, A. K. *Indian J. Heterocycl. Chem.* **2003**, *13*, 131.
- Varma, R. S.; Rastogi, N.; Singh, A. P.; Kapil, A. *Indian J. Heterocycl. Chem.*, **2004**, *13*, 205.
- Mogilaiah, K.; Reddy, Ch. S.; Vidya, K. *Indian J. Heterocycl. Chem.* **2004**, *14*, 145.
- Egawa, H.; Miyamoto, T.; Minamida, A.; Nishimura, Y.; Okada, H.; Uno, H.; Motosumota, T. *J. Med. Chem.* **1984**, *27*, 1543.
- Balin, G. B.; Tan, W. L. *Aust. J. Chem.* **1984**, *37*, 1065.

36. Kuroda, T.; Suzuki, F.; Tamura, T.; Ohmori, K.; Hosie, H. *J. Med. Chem.* **1992**, *35*, 1130.
37. Chen, K.; Kuo, S.; Hsieh, M.; Anthoner, K. *J. Med. Chem.* **1997**, *40*, 3049.
38. Ferrarini, M.; Clendio, M.; Calderone, U.; Lovella, G. *Eur. J. Med. Chem.*, **1998**, *33*, 383.
39. Varma, R. S.; Nobles, W. L. *J. Pharm. Sci.* **1975**, *34*, 881.
40. Cavier, R.; Royer, R.; Rips, R.; Rene, L. *Chim. Ther.* **1969**, *4*, 21.
41. Rajopadhye, M.; Popp, F.D. *Indian J. Heterocycl Chem.* **1984**, *21*, 289.
42. Varma, R. S.; Pandey, R. K. *Indian J. Chem.* **1982**, *21B*, 157.
43. Mogilaiah, K.; Srinivas, K.; Rama Sudhakar, G. *Indian J. Chem.* **2004**, *43B*, 2014.
44. Marvel, C. S.; Heris, G. S. *Organic Synthesis, Coll.* **1941**, *1*, 327.
45. Hawes, E. M.; Wibberley, D. G. *J. Chem. Soc (C)*. **1966**, *5*, 315.
46. Lax, W. *J. Park, Chem (2)*. **1901**, *1*, 63.
47. Weixandt, W. *J. Park, Chem.* **1984**, *49*, 323.